| 查看: 776 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
材料工程085601，270求调剂
已经有24人回复
-
085404 293求调剂
已经有3人回复
-
调剂
已经有21人回复
-
复试调剂，一志愿郑州大学材料与化工289分
已经有15人回复
-
08工科求调剂290分
已经有12人回复
-
286求调剂
已经有16人回复
-
材料类284调剂
已经有24人回复
-
考研调剂-材料类-284
已经有14人回复
-
327求调剂
已经有11人回复
-
一志愿985初试354分生物调剂
已经有3人回复
» 抢金币啦！回帖就可以得到:
-
东北石油大学化学化工学院还有少量调剂名额（化学、化学工程与技术、化学工程专硕）
+1/91
-
四川农业大学（211和双一流）土木学院2026年市政工程（学硕）调剂2名
+1/90
-
中医药广东省实验生物成像团队调剂信息
+1/42
-
江西水利电力大学-理学院-能源动力（储能技术）085808专硕点-接收调剂
+1/41
-
欢迎生物医学工程、药学、生物、冶金、计算机等专业有班长团支书经历的同学-上海
+1/28
-
齐鲁工业大学环境科学与工程学部冯庆课题组招收调剂研究生
+1/23
-
大连大学—六盘水师范学院联培硕士接受调剂
+1/11
-
河南理工大学化学化工学院招生材料、化工等相关专业调剂研究生
+1/10
-
三峡大学材化学院化工新材料课题组现招收化学或者化工、材料硕士研究生2名
+5/10
-
★上海★上海工程技术大学·环境与资源创新中心（ICER）接收化工材料环境等学科调剂生
+1/9
-
中国科学技术大学-安徽大学高薪联合招聘博士后/副研究员
+1/8
-
【华中科技大学】【管理学院】【吴庆华教授团队】【招收2-3名博士后】
+1/8
-
计算机学院招学硕大量调剂
+1/7
-
徐工-环境工程学院-招收调剂硕士
+1/7
-
齐齐哈尔大学李莉课题组诚招2026级考研调剂生（学硕和专硕）
+1/3
-
广州双一流大学08代码学硕接受调剂
+1/3
-
河南理工大学化学化工学院招收材料、化工类专业调剂研究生
+1/3
-
上海应用技术大学刘敏课题组 招生调剂生---欢迎化学，化工，材料，生物等相近方向
+2/2
-
攀枝花学院化学工程、资源与环境硕士接受08（工学）打头专业调剂
+1/1
-
2026年河北大学材料与化工（专硕）调剂和化学生物学学硕调剂
+1/1
|
本帖内容被屏蔽 |
2楼2011-01-10 13:14:23
3楼2011-01-10 13:19:10
4楼2011-01-10 13:20:20
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
|
b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. 术后48小时但不超过5天未使用抗生素所得的腹内脓肿（包括肝，脾）的患者，其脓肿是由于感染所引起的 |
8楼2011-01-12 10:42:52
9楼2011-01-12 10:53:19
10楼2011-01-12 10:59:22
11楼2011-01-12 11:06:34
12楼2011-01-12 11:08:53
13楼2011-01-12 11:28:39
14楼2011-01-12 11:51:32
15楼2011-01-12 11:59:17
痴夷子皮(金币+10):谢谢 2011-01-12 13:46:26
痴夷子皮(金币+5):谢谢 2011-01-12 13:47:35
痴夷子皮(金币+5):谢谢 2011-01-12 13:47:35
|
. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. 感染引起腹腔内脓肿后只使用一种抗生素（单一的广谱药或超过联合用药中的一种抗生素 ，如甲硝唑，氨苄青霉素，庆大霉素） |
16楼2011-01-12 12:11:32
帖子如何关闭？ 17楼2011-01-16 18:39:31
